WO2022090953A1 - Dispersion solide de chlorhydrate de ponatinib et son procédé de préparation - Google Patents
Dispersion solide de chlorhydrate de ponatinib et son procédé de préparation Download PDFInfo
- Publication number
- WO2022090953A1 WO2022090953A1 PCT/IB2021/059921 IB2021059921W WO2022090953A1 WO 2022090953 A1 WO2022090953 A1 WO 2022090953A1 IB 2021059921 W IB2021059921 W IB 2021059921W WO 2022090953 A1 WO2022090953 A1 WO 2022090953A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ponatinib hydrochloride
- solid dispersion
- ponatinib
- solid
- pharmaceutically acceptable
- Prior art date
Links
- 239000007962 solid dispersion Substances 0.000 title claims abstract description 81
- 238000000034 method Methods 0.000 title claims abstract description 44
- BWTNNZPNKQIADY-UHFFFAOYSA-N ponatinib hydrochloride Chemical compound Cl.C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 BWTNNZPNKQIADY-UHFFFAOYSA-N 0.000 title claims description 119
- 229960002183 ponatinib hydrochloride Drugs 0.000 title claims description 117
- 238000002360 preparation method Methods 0.000 title abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 239000007787 solid Substances 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims description 28
- 229920000642 polymer Polymers 0.000 claims description 14
- 238000000935 solvent evaporation Methods 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 13
- 239000012296 anti-solvent Substances 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 8
- 238000009474 hot melt extrusion Methods 0.000 claims description 8
- 239000006185 dispersion Substances 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 238000010668 complexation reaction Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 239000003463 adsorbent Substances 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000008247 solid mixture Substances 0.000 claims 3
- 239000008139 complexing agent Substances 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 34
- 239000000203 mixture Substances 0.000 abstract description 22
- 239000002137 L01XE24 - Ponatinib Substances 0.000 abstract description 19
- 229960001131 ponatinib Drugs 0.000 abstract description 19
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 abstract description 19
- 150000003839 salts Chemical class 0.000 abstract description 8
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 84
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- 238000003756 stirring Methods 0.000 description 20
- 239000008187 granular material Substances 0.000 description 19
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 18
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 18
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 18
- 239000012265 solid product Substances 0.000 description 18
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 15
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 15
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 15
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 13
- 239000007921 spray Substances 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 235000012239 silicon dioxide Nutrition 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 10
- 239000007891 compressed tablet Substances 0.000 description 10
- 239000010408 film Substances 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 9
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 229960004853 betadex Drugs 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- 238000000634 powder X-ray diffraction Methods 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 8
- 229920002554 vinyl polymer Polymers 0.000 description 8
- -1 4-methylpiperazin-l-yl Chemical group 0.000 description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 description 7
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
- 229960001681 croscarmellose sodium Drugs 0.000 description 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 7
- 229940069328 povidone Drugs 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940088679 drug related substance Drugs 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 229910002054 SYLOID® 244 FP SILICA Inorganic materials 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 229920003134 Eudragit® polymer Polymers 0.000 description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920003083 Kollidon® VA64 Polymers 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 229920003072 Plasdone™ povidone Polymers 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001531 copovidone Polymers 0.000 description 2
- 229920000578 graft copolymer Polymers 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229910002024 Aerosil® 200 Pharma Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920003116 HPC-SSL Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 229920003082 Povidone K 90 Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003974 aralkylamines Chemical class 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000008395 clarifying agent Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- CRVGKGJPQYZRPT-UHFFFAOYSA-N diethylamino acetate Chemical compound CCN(CC)OC(C)=O CRVGKGJPQYZRPT-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 238000002464 physical blending Methods 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 239000001194 polyoxyethylene (40) stearate Substances 0.000 description 1
- 235000011185 polyoxyethylene (40) stearate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940117958 vinyl acetate Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Definitions
- the present subject matter relates to a solid oral pharmaceutical composition comprising ponatinib or a pharmaceutically acceptable salt thereof and at least one pharmaceutical acceptable excipient.
- the present subject matter also relates to pharmaceutical compositions comprising a solid dispersion of ponatinib or a pharmaceutically acceptable salt thereof and at least one pharmaceutical acceptable excipient. Furthermore, it also relates to process of preparation of such compositions, and uses thereof.
- Ponatinib hydrochloride has a chemical name 3-(imidazo[l,2-b]pyridazin- 3ylethynyl)-4-methyl-N- ⁇ 4-[(4-methylpiperazin-l-yl)methyl]-3-(trifluoromethyl) phenyl Jbenzamide hydrochloride.
- Ponatinib hydrochloride is represented by the following chemical structure according to Formula (I).
- Ponatinib hydrochloride is a kinase inhibitor which is indicated for the treatment of chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
- CML chronic myeloid leukemia
- Ph+ALL Philadelphia chromosome positive acute lymphoblastic leukemia
- US 8,114,874 describe Ponatinib and its hydrochloride salt and a process for the preparation thereof.
- US 10,221,184 describe Form alpha a propylene glycol solvate and Form beta a benzyl alcohol solvate of Ponatinib hydrochloride and a process of preparation thereof.
- WO 2018232501 describes Form APO-I, Form APO-III, Form APO-IV and Form APO-V of Ponatinib hydrochloride and process of preparation thereof.
- WO 2019246479 describes Form Z an acetic acid solvated hydrate of Ponatinib hydrochloride and a process of preparation thereof.
- Solid dispersions of drugs are generally known to improve the stability and solubility of drug products. However, some of such amorphous solid dispersions are found to be unstable over time. Amorphous solid dispersions of drugs tend to convert to crystalline forms over time, which can lead to improper dosing due to differences of the solubility of crystalline drug material compared to amorphous drug material.
- the present subject matter however provides stable amorphous solid dispersions of Ponatinib hydrochloride with improved solubility and stability and pharmaceutical composition comprising such solid dispersion containing Ponatinib hydrochloride and at least one pharmaceutical acceptable polymer and /or excipient.
- An aspect of the present subject matter is to provide a solid dispersion of Ponatinib hydrochloride together with atleast one pharmaceutically acceptable excipient.
- the solid dispersion of the present subject matter may be manufactured by processes such as adsorption, solvent evaporation, hot melt extrusion, freeze drying, spray drying, lyophilisation, complexation and use of anti-solvent precipitation and Supercritical fluid (SCF) technology.
- processes such as adsorption, solvent evaporation, hot melt extrusion, freeze drying, spray drying, lyophilisation, complexation and use of anti-solvent precipitation and Supercritical fluid (SCF) technology.
- Another aspect of the present subject matter is to provide process for preparation of solid dispersion comprising; a. providing a solution comprising Ponatinib hydrochloride and one or more pharmaceutically acceptable excipients; b. removing solvent from the solution obtained in step (a); and c. isolating a solid dispersion comprising Ponatinib hydrochloride and one or more pharmaceutically acceptable excipient.
- Another aspect of the present subject matter is to provide process for preparing a solid dispersion containing an amorphous form of ponatinib hydrochloride and one or more pharmaceutically acceptable carriers, which comprises; a. providing a solution of Ponatinib or its salt and pharmaceutically acceptable carrier in suitable solvent(s), b. adding antisolvent to the above solution of step (a) c. isolating a solid dispersion containing an amorphous form of Ponatinib or its salt and one or more pharmaceutically acceptable carrier.
- the present subject matter provides a pharmaceutical composition comprising solid dispersion of Ponatinib hydrochloride and atleast one pharmaceutical acceptable excipient.
- the present subject matter relates to a pharmaceutical composition of Ponatinib. More particularly, this subject matter relates to pharmaceutical composition comprising amorphous Ponatinib, and to pharmaceutical compositions comprising a solid dispersion containing Ponatinib and at least one polymer / excipients. Furthermore present subject matter relates to methods for manufacturing such formulations and compositions and use thereof.
- Fig 1 shows the X-ray powder diffractogram ("PXRD") pattern of solid dispersion of Ponatinib hydrochloride with Betadex-HPB obtained from example 5.
- Fig 2 shows the X-ray powder diffractogram ("PXRD") pattern of solid dispersion of Ponatinib hydrochloride with Silicon dioxide obtained from example 18.
- Fig 3 shows the X-ray powder diffractogram ("PXRD") pattern of solid dispersion of Ponatinib hydrochloride with Hypromellose acetate succinate (1:3) obtained from example 12.
- PXRD X-ray powder diffractogram
- Fig 4 shows the X-ray powder diffractogram ("PXRD") pattern of solid dispersion of Ponatinib hydrochloride with Carbopol 71 G obtained from example 15.
- PXRD X-ray powder diffractogram
- Fig 5 shows the X-ray powder diffractogram ("PXRD") pattern of solid dispersion of Ponatinib hydrochloride with HPC (1:3) obtained from example 7.
- the solid dispersion of the present subject matter may be manufactured by processes such as adsorption, solvent evaporation, hot melt extrusion, freeze drying, spray drying, lyophilisation, complexation and use of anti-solvent precipitation and Supercritical fluid (SCF) technology.
- SCF supercritical fluid
- the present subject matter is to provide a solid dispersion of Ponatinib hydrochloride together with atleast one pharmaceutically acceptable excipient, prepared by process comprising; a. providing a solution comprising Ponatinib hydrochloride and one or more pharmaceutically acceptable excipients; b. removing solvent from the solution obtained in step (a); and c. isolating a solid dispersion comprising Ponatinib hydrochloride and one or more pharmaceutically acceptable excipient.
- Another embodiment of the present subject matter is to provide process for preparing a solid dispersion containing an amorphous form of ponatinib hydrochloride and one or more pharmaceutically acceptable carriers, which comprises; a. providing a solution of ponatinib or its salt and pharmaceutically acceptable carrier in suitable solvent(s), b. adding antisolvent to the above solution of step (a) c. isolating a solid dispersion containing an amorphous form of ponatinib or its salt and one or more pharmaceutically acceptable carrier.
- the present subject matter provides a pharmaceutical composition comprising solid dispersion of Ponatinib hydrochloride and atleast one pharmaceutical acceptable excipient.
- the present application relates to a pharmaceutical composition of ponatinib. More particularly, this invention relates to pharmaceutical composition comprising amorphous Ponatinib, and to pharmaceutical compositions comprising a solid dispersion containing Ponatinib and at least one polymer / excipients. Furthermore present subject matter relates to methods for manufacturing such formulations and compositions and to their use. In yet another aspect, the solid dispersion comprising Ponatinib and the polymer and /or excipients is further mixed with one or more pharmaceutically acceptable excipients and / or additives to prepare pharmaceutical composition.
- excipients and / or additives are not particularly limited, so long as they are pharmaceutically acceptable.
- examples of the excipients and / or additives include filler, binder, disintegrant, lubricant, glidant and the like.
- solid dispersion refers to a system in a solid state comprising at least two components, wherein one component is dispersed throughout the other component or components.
- solid dispersion refers to stable solid dispersions comprising amorphous drug substance and one or more polymers or carriers.
- solid dispersion as used herein also refers to stable solid dispersions comprising amorphous drug substance and one or more polymers or carriers with or without adsorbent/absorbent.
- amorphous drug substance it is meant that the amorphous solid contains drug substance in a substantially amorphous solid state form i.e. at least about 80% of the drug substance in the dispersion is in an amorphous form. More preferably at least about 90% and most preferably at least about 95% of the drug substance in the dispersion is in amorphous form.
- a solution in step (a) includes direct use of a reaction mixture containing Ponatinib hydrochloride that is obtained in the course of its synthesis or dissolving Ponatinib hydrochloride and pharmaceutically acceptable carrier in a suitable solvent or a mixture of solvents.
- providing a solution at step (a) may be carried out by dissolving crystalline or amorphous Ponatinib hydrochloride and at least one pharmaceutically acceptable excipient simultaneously or separately in same or different solvents.
- a solution of Ponatinib hydrochloride and the excipient at step (a) may be prepared at any suitable temperatures of about 0°C to reflux temperature of the solvent used.
- a solution of Ponatinib hydrochloride and the excipient may be filtered to make it clear and free of unwanted particles.
- the obtained solution may be optionally treated with an adsorbent material, such as carbon and/or hydrose, to remove coloured components, etc., before filtration.
- amorphous form of Ponatinib hydrochloride may be combined with excipient either by physical blending of both the solid components or by suspending both the components in a suitable solvent and conditions, such that both the components remain unaffected. Blending may be carried out using techniques known in art such as rotatory cone dryer, fluidized bed dryer or the like optionally under reduced pressure / vacuum or inert atmosphere such nitrogen at suitable temperature and sufficient time to obtain uniform composition of amorphous form of Ponatinib hydrochloride and at least one pharmaceutically acceptable excipient.
- the pharmaceutically acceptable polymer / excipients in step (a) include, but are not limited to copovidone, graft copolymer of polyethylene glycol, polyvinyl acetate phthalate, Hypromellose Cp-15, Hypromellose-CP-06 (HP-CP- 06): Polyvinyl pyrollidone-30 (PVP-30), Polyvinyl pyrrolidone-25 (PVP-25), Hypromellose-CP-06, Polyvinyl pyrollidine-90 (PVP-90), Plasdone S-630, Plasdone S-630 Ultra, Silicon dioxide, Silicon dioxide (Syloid 244FP), Silicon dioxide (Syloid AL-1FP/63FP), Silicon dioxide (Syloid XDP), Colloidal silicon dioxide (Aerosil 200 Pharma), Neusilin, Neusilin: Polyvinyl pyrollidine-90 (PVP- 90), Hydroxypropyl cellulose (HPC), Hydroxypropyl cellulose (HPC): Polyvinyl py
- Solid dispersions of the present application also include the solid dispersions obtained by combining Ponatinib hydrochloride with a suitable non-polymeric excipient by employing techniques known in the art or procedures described or exemplified in any aspect of the instant application.
- the present application provides a solid dispersion of Ponatinib hydrochloride together with Hydroxypropyl betadex (HPB-Betadex).
- the present application provides a solid dispersion of Ponatinib hydrochloride together with hydroxyl propyl methyl cellulose acetate succinate (HPMCAS).
- HPMCAS hydroxyl propyl methyl cellulose acetate succinate
- the present application provides a solid dispersion of Ponatinib hydrochloride together with Hydroxypropyl cellulose (HPC).
- HPC Hydroxypropyl cellulose
- the present application provides a solid dispersion of Ponatinib hydrochloride together with croscarmellose sodium (CCS).
- the present application provides a solid dispersion of Ponatinib hydrochloride together with Carbopol 974 P.
- the present application provides a solid dispersion of Ponatinib hydrochloride together with Carbopol 71 G.
- the present application provides a solid dispersion of Ponatinib hydrochloride together with Polyvinylpyrrolidone-90 (PVP-90).
- the present application provides a solid dispersion of Ponatinib hydrochloride together with Polyvinylpyrrolidone-30 (PVP-90).
- the present application provides a solid dispersion of Ponatinib hydrochloride together with Polyvinylpyrrolidone-25 (PVP-90).
- the present application provides a solid dispersion of Ponatinib hydrochloride together with Polyvinylpyrrolidone-25 (PVP-25) and silicon dioxide (Syloid 244FP).
- the present application provides a solid dispersion of Ponatinib hydrochloride together with Polyvinylpyrrolidone-30 (PVP-30) and silicon dioxide (Syloid 244FP). In an embodiment, the present application provides a solid dispersion of Ponatinib hydrochloride together with Polyvinylpyrrolidone-90 (PVP-90) and silicon dioxide (Syloid 244FP).
- the present application provides a solid dispersion of Ponatinib hydrochloride together with Copovidone and silicon dioxide (Syloid 244FP).
- the present application provides a solid dispersion of Ponatinib hydrochloride.
- the present application provides a solid dispersion of Ponatinib hydrochloride together with Hydroxypropyl methyl cellulose.
- the present application provides a solid dispersion of Ponatinib hydrochloride together with silicon dioxide.
- the suitable solvent that can be used include but are not limited to: alcohol solvents such as methanol, ethanol, isopropyl alcohol, n-propanol, 2-butanol and the like; halogenated hydrocarbons such as dichloromethane, 1 ,2-dichloroethane, and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like; esters such as ethyl acetate, n-propyl acetate, n-butyl acetate, t-butyl acetate and the like; ethers such as diethyl ether, dimethyl ether, di-isopropyl ether, anisole, 2-methyl tetrahydrofuran, tetrahydrofuran, 1 ,4-dioxane and the like; hydrocarbons such as heptane, cyclohexane, toluene, xylene
- suitable techniques which can be used for the removal of solvent a solution in step (b) include but not limited to evaporation, flash evaporation, simple evaporation, rotational drying such as drying using a rotavapor, spray drying, agitated thin-film drying, agitated nutsche filter drying, pressure nutsche filter drying, freeze drying, filtration or any other technique known in the art.
- the solid dispersion can also prepared by technique like hot-melt extrusion. The hot-melt extrusion is preferably carried out in the absence of solvent.
- the isolation of a solid dispersion of Ponatinib hydrochloride with excipient at step c) involves recovering the solid obtained in step b).
- the solid obtained from step b) may be recovered using techniques such as by scraping, or by shaking the container, or triturating with a solvent to make slurry followed by filtration, or other techniques specific to the equipment used.
- the solid dispersion of Ponatinib hydrochloride and excipient obtained from step b) may be optionally dried before or after isolating at step c).
- Solid dispersion of Ponatinib hydrochloride obtained at step c) may be optionally combined with at least one additional pharmaceutically acceptable excipient.
- solid dispersion of Ponatinib hydrochloride may be combined with additional excipient using a technique known in art or according to the previous aspects of the present application.
- the stable Ponatinib hydrochloride solid dispersions are suitable for powder handling and downstream processes and highly stable under mechanical stress such as grinding and blending.
- the reaction solution may optionally be treated with carbon, flux-calcined diatomaceous earth (Hyflow) or any other suitable material to remove color, insoluble materials, improve clarity of the solution, and/or remove impurities adsorbable on such material.
- the solution obtained above may be filtered to remove any insoluble particles.
- the insoluble particles may be removed suitably by filtration, centrifugation, decantation, or any other suitable techniques under pressure or under reduced pressure.
- the solution may be filtered by passing through paper, glass fiber, cloth or other membrane material, or a bed of a clarifying agent such as Celite® or Hyflow.
- the filtration apparatus may need to be preheated to avoid premature crystallization.
- compositions comprising a therapeutically effective amount of Ponatinib hydrochloride obtained according to present application, and at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient thereof.
- the X-ray powder diffraction (XRPD) spectrum according to the present subject matter was measured on a PANalytical X'Pert PRO X- Ray Diffractometer.
- the parameters of the X-ray powder diffraction method of the present subject matter were as follows:
- Scan range: from 2.5084 degree to 40.0 degree.
- Ponatinib hydrochloride (1 g) was dissolved in methanol (60 ml) and followed by addition of Betadex-HPB (2 g). The obtained reaction mixture was stirred to obtain a clear solution and filtered through hyflo. The obtained filtrate was concentrated under vacuum followed by addition of isopropyl alcohol (15 ml) and resulting slurry was stirred for 30 min. The obtained solid product was filtered and washed with isopropyl alcohol and dried under vacuum at 40-50°C for 10 hours.
- Ponatinib hydrochloride (1 g) was dissolved in methanol (60 ml) and followed by addition of Betadex-HPB (2 g). The obtained reaction mixture was stirred to obtain a clear solution and filtered through hyflo. The obtained filtrate was concentrated under vacuum followed by addition of acetonitrile (15 ml) and resulting slurry was stirred for 30 min. The obtained solid product was filtered and washed with acetonitrile and dried under vacuum at 40-50°C for 10 hours.
- Ponatinib hydrochloride (1 g) was dissolved in methanol (60 ml) and followed by addition of Betadex-HPB (2 g). The obtained reaction mixture was stirred to obtain a clear solution and filtered through hyflo. The obtained filtrate was concentrated under vacuum followed by addition of ethyl acetate (15 ml) and resulting slurry was stirred for 30 min. The obtained solid product was filtered and washed with ethyl acetate and dried under vacuum at 40-50°C for 10 hours.
- Ponatinib hydrochloride (1 g) was dissolved in methanol (60 ml) and followed by addition of Betadex-HPB (2 g). The obtained reaction mixture was stirred to obtain a clear solution and filtered through hyflo. The obtained filtrate was concentrated under vacuum followed by addition of acetone (15 ml) and resulting slurry was stirred for 30 min. The obtained solid product was filtered and washed with acetone and dried under vacuum at 40-50°C for 10 hours.
- Ponatinib hydrochloride (5 g) was dissolved in methanol (300 ml) and followed by addition of Betadex-HPB (7.5 g). The obtained reaction mixture was stirred to obtain a clear solution and filtered through hyflo. The obtained solution was dried in a spray dryer to obtain solid product.
- Ponatinib hydrochloride (5 g) was dissolved in methanol (300 ml) and followed by addition of Betadex-HPB (6.25 g). The obtained reaction mixture was stirred to obtain a clear solution and filtered through hyflo. The obtained solution was dried in a spray dryer to obtain solid product.
- Ponatinib hydrochloride (4 g) was dissolved in methanol (300 ml) and followed by addition of HPC (12 g). The obtained reaction mixture was stirred to obtain a clear solution and filtered through hyflo. The obtained solution was dried in a spray dryer to obtain solid product.
- Ponatinib hydrochloride (1 g) was dissolved in methanol (60 ml) and followed by addition of HPC (3 g). The obtained reaction mixture was stirred to obtain a clear solution and filtered through hyflo. The obtained filtrate was concentrated under vacuum. The obtained solid product was dried under vacuum at 40-50°C for 10 hours.
- Ponatinib hydrochloride (1 g) was dissolved in methanol (60 ml) to obtain a clear solution and filtered through hyflo. To obtained filtrate added hypromellose acetate succinate (3 g) followed by stirring and solvent concentrated under vacuum. Isopropyl ether (15 ml) added to the reaction mass and resulting slurry was stirred for 30 min. The obtained solid product was filtered and washed with isopropyl ether and dried under vacuum at 40-50°C for 10 hours.
- Ponatinib hydrochloride (1 g) was dissolved in methanol (60 ml) to obtain a clear solution and filtered through hyflo. To obtained filtrate added hypromellose acetate succinate (2.5 g) followed by stirring and solvent concentrated under vacuum. Isopropyl ether (15 ml) added to the reaction mass and resulting slurry was stirred for 30 min. The obtained solid product was filtered and washed with isopropyl ether and dried under vacuum at 40-50°C for 10 hours.
- Ponatinib hydrochloride (1 g) was dissolved in methanol (60 ml) to obtain a clear solution and filtered through hyflo. To obtained filtrate added hypromellose acetate succinate (2 g) followed by stirring and solvent concentrated under vacuum. Isopropyl ether (15 ml) added to the reaction mass and resulting slurry was stirred for 30 min. The obtained solid product was filtered and washed with isopropyl ether and dried under vacuum at 40-50°C for 10 hours.
- Example 12 Preparation of Ponatinib hydrochloride solid dispersion with Hypromellose acetate succinate: Ponatinib hydrochloride (1 g) was dissolved in methanol (60 ml) to obtain a clear solution and filtered through hyflo. To obtained filtrate added hypromellose acetate succinate (3 g) followed by stirring and solvent concentrated under vacuum. The obtained solid product was dried under vacuum at 40-50°C for 10 hours.
- Ponatinib hydrochloride (1 g) was dissolved in methanol (60 ml) to obtain a clear solution and filtered through hyflo. To obtained filtrate added CCS (3 g) followed by stirring and solvent concentrated under vacuum. The obtained solid product was dried under vacuum at 40-50°C for 10 hours.
- Ponatinib hydrochloride (1 g) was dissolved in methanol (60 ml) to obtain a clear solution and filtered through hyflo. To obtained filtrate added Carbopol 974 P (3 g) followed by stirring and solvent concentrated under vacuum. The obtained solid product was dried under vacuum at 40-50°C for 10 hours.
- Ponatinib hydrochloride (1 g) was dissolved in methanol (60 ml) to obtain a clear solution and filtered through hyflo. To obtained filtrate added Carbopol 71 G (3 g) followed by stirring and solvent concentrated under vacuum. The obtained solid product was dried under vacuum at 40-50°C for 10 hours.
- Ponatinib hydrochloride (1 g) was dissolved in methanol (60 ml) to obtain a clear solution and filtered through hyflo. To obtained filtrate added CP-6 (HP-6cps) (3 g) followed by stirring and solvent concentrated under vacuum. The obtained solid product was dried under vacuum at 40-50°C for 10 hours.
- Ponatinib hydrochloride (1 g) was dissolved in methanol (60 ml) to obtain a clear solution and filtered through hyflo. To obtained filtrate added Silicon dioxide (3 g) followed by stirring and solvent con centrated under vacuum. The obtained solid product was dried under vacuum at 40-50°C for 10 hours.
- Example 19 Ponatinib hydrochloride formulation prepared with adsorption
- step 2 Syloid was added to step 1 and dispersion was stirred for 30 mins. 3. Solvent evaporation of step 2 dispersion was carried out in Rotavapor/ Spray Dryer/ Fluidised bed dryer. The solvent was removed under vacuum with desired process parameters.
- the dried milled material was blended with extra granular material in blender and compressed in to tablets.
- the compressed tablets were film coated in perforated coating pan.
- Example 20 Ponatinib hydrochloride formulation prepared with solvent evaporation technology:
- the milled intra granular material was blended with extra granular material and compressed in to tablets.
- Example 21 Ponatinib hydrochloride formulation containing polymer prepared with solvent evaporation technology
- the milled intra granular material was blended with extra granular material followed by compression.
- step 2 Surfactant solution of step 2 was added to API and polymer mix under stirring.
- the dried material was milled through desired screen in quadro co mill.
- the milled intra granular material was blended with extra granular material and compressed in to tablet.
- Examples 23A and 23B Ponatinib hydrochloride formulation prepared with hot melt extrusion
- melt granulated material was milled using suitable screen in quadro comill.
- the milled material was blended with extra granular material in blender and compressed in to tablets.
- Examples 24A and 24B Ponatinib hydrochloride formulation prepared with lyophilization
- step 2 Solution of step 2 was added to API and polymer Mix under stirring for Example 24B.
- Example 24A and 24B The solution obtained for Example 24A and 24B was subjected for solvent evaporation in lyophilizer with desired process parameters.
- the dried material was sifted through desired screen.
- the milled intra granular material was blended with extra granular material and compressed in to tablets.
- Examples 25A, 25B and 25C Ponatinib hydrochloride formulation prepared with complexation
- the dried material was milled through desired screen in quadro co mill.
- the milled intra granular material was blended with extra granular material and compressed in to tablets.
- the blended intra granular material was mixed with extra granular material and compressed in to tablets.
- Anti-solvent water, isopropyl alcohol
- the dispersion formed was subjected to solvent evaporation in Rotavapor/ Spray Dryer/ Fluidised spray dryer with desired process parameters.
- the dried material was milled through desired screen in quadro co mill.
- the milled intra granular material was blended with extra granular material and compressed in to tablets.
- the milled intra granular material was blended with extra granular material and compressed in to tablets.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une composition pharmaceutique orale solide comprenant du ponatinib ou un sel pharmaceutiquement acceptable de celui-ci et au moins un excipient pharmaceutiquement acceptable. La présente invention concerne également des compositions pharmaceutiques comprenant une dispersion solide de ponatinib ou un sel pharmaceutiquement acceptable de celui-ci et au moins un excipient pharmaceutiquement acceptable. De plus, l'invention concerne également un procédé de préparation de telles compositions, et leurs utilisations.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202021047154 | 2020-10-29 | ||
IN202021047154 | 2020-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022090953A1 true WO2022090953A1 (fr) | 2022-05-05 |
Family
ID=81382004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2021/059921 WO2022090953A1 (fr) | 2020-10-29 | 2021-10-27 | Dispersion solide de chlorhydrate de ponatinib et son procédé de préparation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022090953A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015001098A1 (fr) * | 2013-07-04 | 2015-01-08 | Sandoz Ag | Formes cristallines du chlorhydrate de ponatinib |
CN104650086A (zh) * | 2013-11-22 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 盐酸帕纳替尼化合物 |
WO2015085973A1 (fr) * | 2013-12-09 | 2015-06-18 | Zentiva, K.S. | Modifications de sel de chlorhydrate de 3-(2-imidazo[1,2-b]pyridazine-3-yléthynyl)-4-méthyl-n-[4-[(4-méthyl-1-pipérazinyl)méthyl]-3-(trifluorométhyl)phényl] benzamide |
WO2019246479A1 (fr) * | 2018-06-22 | 2019-12-26 | Johnson Matthey Public Limited Company | Forme de ponatinib |
-
2021
- 2021-10-27 WO PCT/IB2021/059921 patent/WO2022090953A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015001098A1 (fr) * | 2013-07-04 | 2015-01-08 | Sandoz Ag | Formes cristallines du chlorhydrate de ponatinib |
CN104650086A (zh) * | 2013-11-22 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 盐酸帕纳替尼化合物 |
WO2015085973A1 (fr) * | 2013-12-09 | 2015-06-18 | Zentiva, K.S. | Modifications de sel de chlorhydrate de 3-(2-imidazo[1,2-b]pyridazine-3-yléthynyl)-4-méthyl-n-[4-[(4-méthyl-1-pipérazinyl)méthyl]-3-(trifluorométhyl)phényl] benzamide |
WO2019246479A1 (fr) * | 2018-06-22 | 2019-12-26 | Johnson Matthey Public Limited Company | Forme de ponatinib |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10034854B2 (en) | Pharmaceutical composition with improved bioavailability | |
JP2003528915A (ja) | カルベジロールの親水性分子分散溶液 | |
JP2020513023A (ja) | ルマテペロンp−トシラートの非晶質形態および固体分散体 | |
US9655885B2 (en) | Amorphous mirabegron and processes for crystal forms of mirabegron | |
US20100015225A1 (en) | Solid dispersion of a neurokinin antagonist | |
JP2021059551A (ja) | フェニルアミノピリミジン誘導体を含む医薬組成物 | |
WO2013089479A1 (fr) | Dispersion solide contenant du célécoxib et son procédé de préparation | |
US20220056012A1 (en) | Amorphous form of a malt1 inhibitor and formulations thereof | |
WO2021125797A1 (fr) | Composition présentant une solubilité et une biodisponibilité améliorées de l'olaparib | |
US20190300483A1 (en) | POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT | |
WO2019220352A1 (fr) | Dispersion solide amorphe de sulfate de larotrectinib et procédé associé | |
KR101151890B1 (ko) | 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법 | |
WO2022090953A1 (fr) | Dispersion solide de chlorhydrate de ponatinib et son procédé de préparation | |
US20160339074A1 (en) | Pharmaceutical composition of selective hcv ns3/4a inhibitors | |
TW202408525A (zh) | 包含帽依賴性核酸內切酶抑制劑的藥物組合物 | |
WO2023152773A1 (fr) | Formes solides de sels de momélotinib et procédés améliorés pour la préparation de momélotinib | |
WO2023195956A1 (fr) | Comprimé revêtu d'un film comprenant du sélexi̇pag et au moins une charge |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21885473 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21885473 Country of ref document: EP Kind code of ref document: A1 |